Monoclonal antibodies disappoint in early Parkinson's disease
Two monoclonal antibodies targeting aggregated α-synuclein have failed to improve clinical or imaging measures of early-stage Parkinson’s disease
United Kingdom United States Gennaro Pagano Roche Innovation Center Basel Movement Disorder Society Alan Whone University Of Bristol Tien Dam
Source: medwirenews.com